<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2786">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04422470</url>
  </required_header>
  <id_info>
    <org_study_id>CHRONOS19</org_study_id>
    <nct_id>NCT04422470</nct_id>
  </id_info>
  <brief_title>Registry of Patients With Hematologic Disease and COVID-19 in Russia</brief_title>
  <acronym>CHRONOS19</acronym>
  <official_title>Observational Prospective Cohort Study - Registry of Patients With Hematologic Disease and COVID-19 in Russia (CHRONOS19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Center for Hematology, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for Cancer Research Support (RakFond)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Enrollme.ru LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Research Center for Hematology, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational prospective cohort study to evaluate the clinical course and
      outcomes of COVID-19 and the underlying disease in patients with hematologic disease
      (malignant or non-malignant).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a web-based registry. After registration, physicians from hematology clinical centers
      and hospitals in Russia will receive access to the web platform for clinical trial management
      to fill in the online data collection form in a de-identified manner. This form includes
      questions about general clinical history of hematologic disease, manifestation, treatment,
      and the course of COVID-19, concomitant conditions, consequences on the hematologic disease,
      short-term and long-term outcomes. It will take approximately 10 min to answer the questions.
      Patients will be followed for 30 days after COVID-19 diagnosis and up to 6 months for
      hematologic disease outcomes and overall survival assessment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">July 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 22, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>30-day all-cause mortality</measure>
    <time_frame>30 day</time_frame>
    <description>Rate of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COVID-19 complications</measure>
    <time_frame>30 day</time_frame>
    <description>Rate of COVID-19 complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU admission</measure>
    <time_frame>30 day</time_frame>
    <description>Rate of ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation / O2 requirement</measure>
    <time_frame>30 day</time_frame>
    <description>Rate of mechanical ventilation / O2 requirement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse or progression of hematologic disease</measure>
    <time_frame>30 day, 90 day and 180 day</time_frame>
    <description>Rate of relapse or progression of hematologic disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>30 day, 90 day and 180 day</time_frame>
    <description>Number of patients alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors</measure>
    <time_frame>30 day, 90 day and 180 day</time_frame>
    <description>Putative risk factors for the severity and lethality of COVID-19</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronavirus Infection and Hematologic Diseases</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional study</intervention_name>
    <description>Non-interventional study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with blood disease (both malignant and non-malignant) infected with SARS-CoV-2
        infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age 18 or older

          -  Any previously or currently diagnosed hematologic disease

          -  Laboratory confirmed or suspected (based on clinical symptoms and/or CT) COVID-19

          -  Known outcome of COVID-19 in case of retrospective data input (protocol allows
             retrospective data input for patients who were prospectively followed in local
             centers)

        Exclusion Criteria

        • Loss of follow-up within 30 days after COVID-19 diagnosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Hospital n.a. S.P. Botkin</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Vorobyev</last_name>
      <phone>+7 (499) 490-03-03</phone>
      <email>morela@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Center for Hematology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Gavrilina, PhD</last_name>
      <phone>+79629745058</phone>
      <email>dr.gavrilina@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital N.A. Semashko</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Samoylova</last_name>
      <phone>+7 (831) 438-95-29</phone>
      <email>official@semashko.nnov.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Russian Scientific Research Institute of Hematology and Transfusiology</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail Fominyh</last_name>
      <phone>+7 (812) 710-23-09</phone>
      <email>m.s.fominyh@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republic Clinical Hospital n.a. N.A. Semashko</name>
      <address>
        <city>Ulan-Ude</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oxana Ochirova</last_name>
      <phone>+7 (3012) 23-08-16</phone>
      <email>rkbsemashko@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Vladimir</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Panteleeva</last_name>
      <phone>+7 (4922) 40-71-26</phone>
      <email>vlad_okb@vladokb.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeriy Lapin</last_name>
      <phone>+7 (4852) 58-23-42</phone>
      <email>okb76@яокб.рф</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Blood diseases</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

